Cath Lab

The catheterization lab channel includes content related to interventional technologies for coronary and peripheral artery disease (PAD). Other cath lab transcatheter device technologies covered on this page included percutaneous treatment for stroke, venous interventions, heart valves, hypertension, heart failure and percutenous coronary interventions (PCI).

News | Cardiac Rehabilitation

January 15, 2020 – Too few people covered by Medicare participated in outpatient cardiac rehabilitation after a heart ...

Home January 15, 2020
Home
News | Heart Valve Technology

January 13, 2020 — The U.S. Food and Drug Administration (FDA) has approved clinical trial that will compare the ...

Home January 13, 2020
Home
Videos | Cath Lab

Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant ...

Home January 09, 2020
Home
Videos | Hemodynamic Support Devices

Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, and Melissa Smith ...

Home January 09, 2020
Home
News | Cath Lab | Dave Fornell, Editor

January 2, 2020 — In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdre ...

Home January 02, 2020
Home
This photo is from a MitraClip procedure during the University of Colorado visit last December.
Feature | Dave Fornell, Editor
Here are the top performing 25 videos posted to the DAIC website in the past year, based on Google Analytics. These the ...
Home December 30, 2019
Home
News | Radial Access

December 30, 2019 — Merit Medical Systems Inc., a leading manufacturer of proprietary devices used primarily in ...

Home December 30, 2019
Home
News | Cardiovascular Business

December 30, 2019 — Most patients do not understand or recall information given to them before heart procedures. For ...

Home December 30, 2019
Home
The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).
Feature | Antiplatelet and Anticoagulation Therapies

December 27, 2019 — The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of ...

Home December 27, 2019
Home
Blog | Cardiovascular Business
With all eyes on rising healthcare costs, reprocessing of single-use devices has become an increasingly important ...
Home December 23, 2019
Home
Videos | Radiation Dose Management

 


Mahadevappa Mahesh, Ph.D., chief of medical physicist and professor of radiology and medical physics, Johns Hopkins ...

Home December 19, 2019
Home
Videos | RSNA

DAIC Editor Dave Fornell and Imaging Technology News (ITN) Consulting Editor Greg Freiherr offer a post-game report on ...

Home December 18, 2019
Home
News | Cath Lab

December 18, 2019 — Cook Medical initiated a recall of its CrossCath Support Catheters in November, which the U.S. Food ...

Home December 18, 2019
Home
The most popular content in the month of November on DAIC was by far the data from the late-breaking trials from the American Herart Association (AHA) 2019 meeting. The second item on this month's list is an overview of key heart failure takeaways from AHA by Nasrien Ibrahim, M.D., associate director of resynchronization and advanced cardiac therapeutics at Massachusetts General Hospital.  Photo by Scott Morgan/AHA.
Feature

December 16, 2019 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) ...

Home December 17, 2019
Home
Vascepa pill contains a concentrated form of fish oil, icosapent ethyl, indication for prevention. The U.S. Food and Drug Administration (FDA) Dec. 13, 2019, approved the use of Vascepa (icosapent ethyl) capsules as an adjunctive therapy to reduce the risk of cardiovascular events in adults with elevated triglyceride levels.
Feature | Pharmaceuticals | Dave Fornell, Editor

December 16, 2019 — The U.S. Food and Drug Administration (FDA), on Dec. 13, approved the use of Vascepa (icosapent ...

Home December 16, 2019
Home
Subscribe Now